@article{oai:air.repo.nii.ac.jp:00005664,
 author = {Satoshi, Kumagai and Yuki  Wada and Akira Anbai and Noriko Takagi and Eriko Okuyama and Manabu Hashimoto},
 issue = {3/4},
 journal = {秋田医学},
 month = {Mar},
 note = {Stereotactic body radiotherapy (SBRT) uses hypofractionated and more precise irradiation methods, and has the advantages of shorter duration, better outcomes, and fewer side effects than conventional radiotherapy. However, the optimal dosage remains unclear. The purpose of the study was to analyze our preliminary treatment results and safety. We retrospectively analyzed 32 patients (primary cancer, 22 ; metastatic cancer, 10) who underwent SBRT for pulmonary tumors at our hospital from April 2015 to June 2020. SBRT was performed with escalated dose prescriptions (up to 55Gy in 4 fractions/64Gy in 8 fractions for peripheral/central lesions, respectively). We evaluated the local control rate (LC rate), overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and adverse events. The target lesions comprised 22 primary lung cancers and 13 metastatic lung cancers. The 2-year LC, OS, PFS, and DSS rates were 82.5%, 68.3%, 50.5%, and 88.0% for primary lung cancer patients and 83.1%, 29.9%, 23.1%, and 48.6% for metastatic lung cancer patients, respectively. Five cases of radiation pneumonitis of grade 2 or higher, one of grade 1 dermatitis and 1 of esophagitis were observed as adverse events. We showed that the treatment outcomes of SBRT for primary and metastatic lung cancers were mostly acceptable.},
 pages = {85--98},
 title = {SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY},
 volume = {48},
 year = {2022}
}